UNLEASHING THE THERAPEUTIC POTENTIAL OF MRGPRs
Employees: 11-50
Total raised: $237.5M
Founded date: 2017
Investors 7
Funding Rounds 3
| Date | Series | Amount | Investors |
| 28.11.2022 | Series C | $120M | - |
| 12.10.2020 | Series B | $77.5M | - |
| 10.05.2018 | Series A | $40M | - |
Mentions in press and media 15
| Date | Title | Description |
| 17.11.2023 | Simulocity Announces New Virtual Conference Center for Escient Pharmaceuticals | ORLANDO, FLORIDA, UNITED STATES, November 17, 2023 /EINPresswire.com/ -- Simulocity, a leading provider of innovative business solutions, is pleased to announce that they will be introducing a new technology as part of their partnership wit... |
| 28.11.2022 | Escient Pharmaceuticals Announces $120 Million Series C Financing | SAN DIEGO–(BUSINESS WIRE)–Escient Pharmaceuticals, a clinical-stage company advancing novel small molecule therapeutics for the potential treatment of a broad range of neurosensory-inflammatory disorders, today announced the closing of a $1... |
| 28.11.2022 | Escient Pharmaceuticals acquires $120M of Series C Funding to advance their pipeline of products | - |
| 12.10.2020 | Escient Raises $77.5M Series B | Photo Courtesy of Escient Pharmaceuticals. San Diego biotech Escient Pharmaceuticals reeled in $77.5 million in its latest funding round. San Diego-based biotech Escient Pharmaceuticals, has announced it has raised a $77... Take 1 minute to... |
| 14.09.2020 | Escient Pharmaceuticals has raised a $75.5 Million Series B funding round and begins clinical trials for their compound targeted at treating Cholestatic and Uremic Pruritus | - |
| 14.09.2020 | Escient Pharmaceuticals Raises $77.5 Million Series B Round and Initiates a Phase I/Ib Clinical Trial of EP547, a MRGPR-Targeted Therapy to Treat Cholestatic and Uremic Pruritus | - |
| 14.09.2020 | Escient Pharmaceuticals Finds $77.5M In Series B | San Diego-based Escient Pharmaceuticals, which is developing treatments for mast cell-related diseases, said on Monday that it has raised $77.5M in a Series B funding round. According to the company, the funding round was led by Sanofi Vent... |
| 10.05.2018 | Escient Pharmaceutials Closes $40m in Series A Funding | Escient Pharmaceutials, a San Diego, CA-based biotech company, closed $40m in Series A funding. Backers included The Column Group, 5AM Ventures and Osage University Partners. In conjunction with the funding, JJ Kang, Ph.D., Principal at The... |
| 09.05.2018 | Top tech startup news stories you need to know this Wednesday, May 9 | Good morning! Here are some of the top tech startup news stories today Wednesday, May 9. Glassdoor announced it has agreed to be acquired by Recruit Holdings Co., Ltd. for $1.2 billion in an all-cash transaction. Glassdoor is a leading job... |
| 09.05.2018 | Escient Pharmaceuticals Launches with $40 Million Series A Financing | - |
Show more